Similarly in a randomized, double-blind, phase III study (CheckMate 511), NIVO1 + IPI3 was compared with NIVO3 + IPI1 in patients with previously untreated, unresectable stage III or IV melanoma [59]. Here, TEX10 is linked to melanoma.